Sareum Holdings PLC Company Presentation at BioTrinity (0137L)
28 Aprile 2020 - 8:00AM
UK Regulatory
TIDMSAR
RNS Number : 0137L
Sareum Holdings PLC
28 April 2020
28 April 2020
Sareum Holdings PLC
("Sareum" or the "Company")
Sareum to Present at BioTrinity 2020
Sareum Holdings plc (AIM:SAR) , the specialist small molecule
drug development business , announces that its CEO, Dr Tim
Mitchell, will give a Company presentation at BioTrinity 2020,
which will be delivered digitally from 28 April to 1 May 2020.
The presentation will provide an update of Sareum's two
proprietary TYK2/JAK1 kinase inhibitor programmes, SDC-1801 and
SDC-1802, targeting autoimmune diseases and cancers, respectively.
Dr Mitchell will also highlight the emerging potential of this
mechanism to modulate the severe inflammatory responses and
respiratory symptoms arising from coronavirus and other viral
infections.
Key cytokines that are found elevated in Covid-19 patients that
have been admitted to intensive care include IL-2, IL-7, IL-10 and
G-CSF*, all of which signal via JAK-family kinases. As the Company
noted in its half yearly report, a paper in the European
Respiratory Journal published in 2017** suggested that TYK2
inhibition might be effective in the treatment of influenza driven
secondary bacterial pneumonia, which is potentially highly relevant
against the backdrop of the Covid-19 pandemic. The Company also
notes that it is preparing grant applications to fund studies to
assess the potential use of its TYK2/JAK1 inhibitors to address
this threat to global public health.
The presentation will be made through the BioTrinity virtual
portal and will be available to registered participants during the
conference and until at least 9 May 2020 -
https://biotrinity.com/showcase .
A copy of the presentation will also be made available on
Sareum's website - www.sareum.co.uk .
BioTrinity is a long-running and highly regarded life sciences
conference. It focuses on partnering, investment and collaboration,
with the core delegate mix including early-stage and emerging
biotech, medtech and digital health companies, big pharma
executives and life sciences investors.
All aspects of the BioTrinity 2020 conference will be delivered
in a digital format.
*C Huang et al. Clinical features of patients infected with 2019
novel coronavirus in Wuhan, China (2020 ) Lancet 395(10223)
497-606)
**J Berg et al. TYK2 as a target for immune regulation in human
viral/bacterial pneumonia. (2017) European Respiratory Journal 50:
1601953
This announcement contains inside information for the purposes
of Article 7 of Regulation 596/2014
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497 700
Strand Hanson Limited (Nominated Adviser)
James Dance / Richard Tulloch 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce / John Beresford-Peirse 020 3764 2341
Citigate Dewe Rogerson (Financial PR)
Mark Swallow/ David Dible 020 7638 9571
About Sareum
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune disease. The Company aims to generate value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases
(SDC-1801) and cancers (SDC-1802). The Company is targeting
completion of preclinical development for each molecule in
2020.
The Company's preclinical FLT3+Aurora inhibitor programme
targeting haematological cancers is licensed to a China-based
specialty pharma company.
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in
genetically defined patients.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research in collaboration with Sareum, and
with funding from Sareum and Cancer Research UK. SRA737 was
licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc., which
is currently seeking to on-license SRA737 to a third party for
further development.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at
www.sareum.co.uk.
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESSEUFDWESSEIL
(END) Dow Jones Newswires
April 28, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Sareum (LSE:SAR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sareum (LSE:SAR)
Storico
Da Apr 2023 a Apr 2024